Nuwellis To Implement 1-for-9 Reverse Stock Split; Stock Down

Nuwellis (NUWE) announced a 1-for-9 reverse stock split, effective October 27, 2026. The company reported Q2 2026 revenue of $2.0M, up 14% YoY, and a net loss of $4.8M. Shares are down 12.48% to $4.70.

Original reporting
Published Oct 28, 2026, 3:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 4:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$NUWE
Bearish
medium confidence
Mentioned
$NUWE
Relevance
5/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$NUWEBearishLow
01

Why it matters

The split and Q2 loss suggest short‑term downside, but the 14% revenue growth hints at a modest top‑line improvement.

02

Market read

Micro‑cap investors will reassess valuation post‑split; broader market impact is negligible.

03

What to watch

Potential upcoming FDA filings or new contract announcements could offset the negative bias from the split.

Relevance 5/10Novelty 5/10Timing: post‑split announcement

Background

NUWE is a medical‑device firm focused on ultrafiltration therapy devices. The reverse split reduces share count nine‑to‑one, changing the CUSIP and potentially affecting share liquidity.

Company-level read

Ticker impact

$NUWEBearishMedium confidence
Context

NUWE announced a 1-for-9 reverse stock split effective Oct 27, 2026 and reported Q2 2026 results.

Expected impact

likely downward pressure as the market prices in the split and recent loss

Evidence & confidence

Reverse splits on micro‑caps typically trigger sell‑offs; the company also posted a net loss of $4.8 M, reinforcing negative sentiment.

Market effects

Limited impact beyond the niche ultrafiltration device market; may signal financing pressure for similar micro‑caps.

Primarily U.S. over‑the‑counter micro‑cap segment; no broader regional effect.

Minimal; the news is company‑specific.

Counterpoint

If the split consolidates the shareholder base, it could improve liquidity and set the stage for a future upside.

Key entities

  • Nuwellis, Inc.

    Medical‑device company issuing the reverse split.

Related articles

$NUWEMed

Nuwellis Reports Third Quarter 2026 Financial Results and Business Update Highlighted by 430 Basis Point Gross Margin Expansion and 13% Reduction in…

Nuwellis, Inc. (NUWE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Nuwellis Reports Third Quarter 2026 Financial Results and Business Update Highlighted by 430 Basis Point Gross Margin Expansion and 13% Reduction in Operating Expenses, Driving 24% Improvement in Operating Loss Console unit sales increased 88% year-to-date versus pri

$NUWEHighAI 8/10

Nuwellis submits FDA application for pediatric Aquadex expansion

Nuwellis (NASDAQ: NUWE) submitted a 510(k) application to the FDA to expand the use of its Aquadex SmartFlow System to pediatric patients weighing 5 kg and above, currently cleared for 20 kg and above. The submission includes clinical data from the ULTRA-Peds Registry and aims to provide treatment options for fluid overload in smaller children. The company's CEO and a medical director commented on the strategic importance and clinical benefits of the expansion.

$NUWEMed

Nuwellis Reports Second Quarter 2026 Financial Results and Business Highlights Focused on Double Digit Revenue Growth and Expanded Gross Margin

Nuwellis, Inc. (NUWE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE August 13, 2026 Nuwellis Reports Second Quarter 2026 Financial Results and Business Highlights Focused on Double Digit Revenue Growth and Expanded Gross Margin Recent capital raise and warrant exercises extend cash runway through second quarter

$NUWEMed

Nuwellis Slumps on Share Sale

Nuwellis (NASDAQ: NUWE) entered a definitive securities purchase agreement for a registered direct offering of 1,310,890 shares at $2.59 per share, with gross proceeds of about $3.1 million from warrant exercises tied to its June 2026 offering. In a concurrent private placement, investors receive warrants for up to 1,310,890 shares at $2.59, exercisable immediately, expiring in five years. Closing expected around Aug. 3, 2026.

$GCTKMed

Top Biotech Gainers: GCTK On The Move, BHC, CORT Boost FY'26 Outlook, NEOG On Watch

Today's top gainers included Glucotrack, whose subsidiary announced progress in the development strategy for LT-100, a novel non-narcotic therapy; Nuwellis, following expanded clinical recognition for its Aquadex therapy; Bausch Health, after reporting strong second-quarter 2026 results and raising its outlook; and Corcept Therapeutics, after posting robust second-quarter 2026 results, among others. Read on… GCTK's LT-100 Program Moves Forward Glucotrack Inc.